Evidence map›Paper›PMID 26106605›Full record

ArticleBioMed research international2015

DNA Methylation Levels of Melanoma Risk Genes Are Associated with Clinical Characteristics of Melanoma Patients.

Érica S S de Araújo, Dimitrius T Pramio, André Y Kashiwabara, Paula C Pennacchi, Silvya S Maria-Engler, Maria I Achatz, Antonio H J F M Campos, João P Duprat, Carla Rosenberg, Dirce M Carraro and 1 more

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Metabolic Reprogramming in Melanoma: An Epigenetic Point of View.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  2. Genetic effects on the skin methylome in healthy older twins.American journal of human genetics · 2024
    Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Érica S S de AraújoInternational Research Center, A.C.Camargo Cancer Center, Rua Taguá 440, 01508010 São Paulo, SP, Brazil.
Dimitrius T PramioInternational Research Center, A.C.Camargo Cancer Center, Rua Taguá 440, 01508010 São Paulo, SP, Brazil.
André Y KashiwabaraFederal Technological University of Paraná, Avenida Alberto Carazzai 1640, 86300000 Cornélio Procópio, PR, Brazil.
Paula C PennacchiSchool of Pharmaceutical Sciences, University of São Paulo, Avenida Professor Lineu Prestes 580, 05508000 São Paulo, SP, Brazil.
Silvya S Maria-EnglerSchool of Pharmaceutical Sciences, University of São Paulo, Avenida Professor Lineu Prestes 580, 05508000 São Paulo, SP, Brazil.
Maria I AchatzInternational Research Center, A.C.Camargo Cancer Center, Rua Taguá 440, 01508010 São Paulo, SP, Brazil ; Department of Oncogenetics, A.C.Camargo Cancer Center, Rua Professor Antônio Prudente 211, 01509010 São Paulo, SP, Brazil.
Antonio H J F M CamposDepartment of Pathology, A.C.Camargo Cancer Center, Rua Professor Antônio Prudente 211, 01509010 São Paulo, SP, Brazil.
João P DupratSkin Cancer Department, A.C.Camargo Cancer Center, Rua Professor Antônio Prudente 211, 01509010 São Paulo, SP, Brazil.
Carla RosenbergDepartment of Genetics and Evolutionary Biology, Institute of Biosciences, University of São Paulo, Rua do Matão 277, 05508090 São Paulo, SP, Brazil.
Dirce M CarraroInternational Research Center, A.C.Camargo Cancer Center, Rua Taguá 440, 01508010 São Paulo, SP, Brazil.
Ana C V KrepischiInternational Research Center, A.C.Camargo Cancer Center, Rua Taguá 440, 01508010 São Paulo, SP, Brazil ; Department of Genetics and Evolutionary Biology, Institute of Biosciences, University of São Paulo, Rua do Matão 277, 05508090 São Paulo, SP, Brazil.
AC Camargo Hospital · BRUniversidade de São Paulo · BRUniversidade Tecnológica Federal do Paraná · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In melanoma development, oncogenic process is mediated by genetic and epigenetic mutations, and few studies have so far explored the role of DNA methylation either as predisposition factor or biomarker. We tested patient samples for germline CDKN2A methylation status and found no evidence of inactivation by promoter hypermethylation. We have also investigated the association of clinical characteristics of samples with the DNA methylation pattern of twelve genes relevant for melanomagenesis. Five genes (BAP1, MGMT, MITF, PALB2, and POT1) presented statistical association between blood DNA methylation levels and either CDKN2A-mutation status, number of lesions, or Breslow thickness. In tumors, five genes (KIT, MGMT, MITF, TERT, and TNF) exhibited methylation levels significantly different between tumor groups including acral compared to nonacral melanomas and matched primary lesions and metastases. Our data pinpoint that the methylation level of eight melanoma-associated genes could potentially represent markers for this disease both in peripheral blood and in tumor samples.

Indexed as

Epigenesis, GeneticCpG IslandsDNA MethylationFemaleGenome, HumanHumansMaleMelanomaMutationPromoter Regions, GeneticRisk FactorsSkin Neoplasms

Identifiers

PMID26106605
PMCPMC4461735
OpenAlexW2050332366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.